Koppert, England, and Zylidac Show the Commercial Bottleneck Has Moved to Scale-Up

Biologicals and precision ag are entering a new phase where the hard part is no longer getting approved, but getting made, supplied, and adopted at scale.

Updated

What is this trend?

Commercial ag biology is shifting from proving efficacy and securing approvals to scaling reproducible manufacturing, supply, and in-program adoption.

  • Approval is no longer the main hurdle; execution and scale-up are.
  • Products win by fitting existing spray and seed programs, not replacing them.
  • Brazil and Europe are becoming key proving grounds for commercial biology.
  • Manufacturing consistency and supply chain readiness now shape market access.
  • Investors should favor firms that pair local registration with scalable production.

What’s the latest?

Koppert’s Brazil launch of Macan is the clearest sign yet that the next commercial hurdle is execution, not approval.

Harvest Robotics Faces Payback Pressure, Biologicals Hit Scale-Up, and Uptime Software Takes Over

How it developed

  1. Reusable autonomy layers, integrated water-efficiency stacks, low-cost selective spraying, and regulated bioinputs
    • Regulatory Pathways Are Turning Biology Into Commercial Crop Inputs

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in AgTech & Precision Ag

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.